Resolve Biosciences Joins EMBL’s Corporate Partnership Programme

Press releases – Resolve Biosciences, Dec. 09, 2021

Single-cell spatial analysis pioneer continues to invest in initiatives that train and support the next generation of molecular life scientists

MONHEIM AM RHEIN, Germany – Dec. 9, 2021 – Resolve Biosciences, the pioneer in Molecular Cartography™, today announced a corporate partnership with the European Molecular Biology Laboratory (EMBL). As part of the EMBL’s Corporate Partnership Programme (CPP), Resolve Biosciences will support molecular life science training. The financial support will enable young researchers to attend scientific conferences and courses, where they can present exciting new discoveries, and interact with scientific leaders from around the globe.

EMBL is the leading life science laboratory in Europe with more than 80 independent research groups covering the spectrum of molecular biology. The CPP was founded in 2009 to support collaboration and training for the next generation of molecular life scientists. The programme aims to connect industry leaders with leading molecular life scientists and biomedical researchers.

“EMBL warmly welcomes Resolve Biosciences to our Corporate Partnership Programme, and we look forward to working together to offer more inclusive access to our world-leading advanced scientific training for scientists who may otherwise be unable to participate,” said Edith Heard, EMBL Director General. “EMBL was established nearly 50 years ago to promote and enhance the life sciences across Europe, and the CPP plays an important role by helping support the development and promotion of innovative and groundbreaking scientific events in Europe.”

“EMBL is a world-renowned center for excellence known for its ongoing commitment to identifying, supporting, and training the next generation of scientists. The team at Resolve Biosciences is proud to continue this legacy and be part of EMBL’s Corporate Partnership Programme,” said Jason T. Gammack, Co-founder and CEO of Resolve Biosciences. “Spatial biology is the new frontier in biomedical research, and we look forward to enabling more researchers to apply the power of our groundbreaking Molecular Cartography technology to resolve the most daunting challenges in biology.”
For more information on EMBL’s Corporate Partnership Programme, please visit
https://www.embl.org/about/info/support/embl-corporate-partnership-programme.

About European Molecular Biology Laboratory

EMBL is Europe’s flagship laboratory for the life sciences. We are an intergovernmental organisation established in 1974 and are supported by 27 member states, two prospective member states and an associate member state. EMBL performs fundamental research in molecular biology, studying the story of life. We offer services to the scientific community; train the next generation of scientists and; strive to integrate the life sciences across Europe. We are international, innovative and interdisciplinary. We are more than 1,800 people, from more than 80 countries, operating across six sites in Barcelona (Spain), Grenoble (France), Hamburg (Germany), Heidelberg (Germany), Hinxton (UK) and Rome (Italy). Our scientists work in independent groups and conduct research and offer services in all areas of molecular biology. Our research drives the development of new technology and methods in the life sciences. We work to transfer this knowledge for the benefit of society. For more information, please visit www.embl.org.

About Resolve Biosciences

Resolve Biosciences is applying the power of Molecular Cartography to enable scientists to gain new insights based on the highest-resolution view of spatial biology. The platform features the company’s proprietary, highly multiplexed, single-molecule detection technology, which offers full spatial context at subcellular resolution, all in a fully automated workflow that preserves the sample tissue. The Molecular Cartography technology offers unparalleled sensitivity and specificity that helps scientists detect individual transcripts and rare signals to interpret fundamental biology and rapidly advance the understanding of complex biological questions in critical fields such as oncology, neuroscience, and infectious disease. The technology has been under development since 2016 and is currently available through Resolve Biosciences’ commercial service laboratory. Resolve Biosciences is privately held and based in Monheim am Rhein, Germany, with a North American facility and laboratory in San Jose, Calif. For additional information, visit www.resolve-biosciences.com.

Resolve Biosciences, the Resolve Biosciences logo, and Molecular Cartography are trademarks of Resolve Biosciences Inc.

Media Contacts

Resolve Biosciences
Andrew Noble
+1 (415) 722-2129
andrew@bioscribe.com

Image of

Close